LaserSight receives $4 million for patent licence:
This article was originally published in Clinica
Executive Summary
An unnamed party has paid $4 million to US company LaserSight in exchange for a worldwide, exclusive royalty-free patent licence covering the vascular and cardiovascular rights included in the patents recently acquired from IBM (see Clinica No 773, p 13). LaserSight is in discussions with other potential licensees in both the ophthalmic and non-ophthalmic fields.